Biomet buyers begin tender offer

The group of private-equity firms that last week sweetened its offer to buy Biomet Inc. today began a tender offer to buy the Warsaw medical device maker’s shares for about $11.4 billion. The offer of $46 a share, which expires at the end of July 11, is contingent upon at least 75 percent of all shares being tendered.

A tender offer avoids a shareholder vote, allowing a buyer to more quickly acquire a company. It also gives the buyer direct ownership of a majority of a company’s shares.

Biomet’s prospective buyers are LVB Acquisition LLC, Goldman Sachs & Co., Kohlberg Kravis Roberts and Texas Pacific Group. The consortium raised its offer last week after a Maryland shareholder-advisory firm urged shareholders to reject the previous offer of $10.9 billion.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}